First, Roche announced that the FDA has accepted its supplemental Biologics License Application for a combination of Lunsumio (mosunetuzumab) and Polivy (polatuzumab vedotin) for patients with relapsed or refractory large B-cell lymphoma. The filing is supported by data showing the combination significantly improved progression-free survival compared with standard treatment options, potentially offering a new chemotherapy-free approach for patients whose disease has returned after prior therapy.
Next, Merck received FDA approval for CAPVAXIVE, its 21-valent pneumococcal conjugate vaccine, in children and adolescents aged 2 through 17 years who are at increased risk for pneumococcal disease. The expanded indication extends protection to a vulnerable pediatric population and reflects growing efforts to broaden vaccine coverage against pneumococcal serotypes associated with invasive disease.
Finally, all eyes were on the FDA's Vaccines and Related Biological Products Advisory Committee as members evaluated Moderna's mRNA-based influenza vaccine, MFLUSIVA. The panel voted unanimously that the vaccine's benefits outweigh its risks for adults aged 50 and older, a recommendation that could pave the way for the first mRNA-based seasonal flu vaccine in the United States. The decision follows a closely watched regulatory review process and could have broader implications for future mRNA vaccine development beyond COVID-19.
Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.
Key Insights
- Roche moves closer to a potential new treatment option for relapsed or refractory large B-cell lymphoma.
- Merck expands CAPVAXIVE's reach to high-risk pediatric patients.
- Moderna's mRNA flu vaccine clears a major regulatory hurdle with unanimous advisory committee support.
